Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
作者信息
Kallen Michael E, Koka Rima, Singh Zeba, Sanchez-Petitto Gabriela, Zaman Qamar U, Yared Jean A, Duong Vu H
机构信息
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
出版信息
Leuk Res. 2020 Sep;96:106406. doi: 10.1016/j.leukres.2020.106406. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
Leuk Res. 2020 Sep;96:106406. doi: 10.1016/j.leukres.2020.106406. Epub 2020 Jun 25.
2
Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
Clin Adv Hematol Oncol. 2018 Apr;16(4):247-249.
3
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695.
4
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
5
Positive First Trial of Enasidenib for AML.
Cancer Discov. 2017 Aug;7(8):OF1. doi: 10.1158/2159-8290.CD-NB2017-098. Epub 2017 Jun 28.
6
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Future Oncol. 2018 Jan;14(1):23-40. doi: 10.2217/fon-2017-0392. Epub 2017 Sep 18.
7
Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib.
Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.
8
Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Clin Adv Hematol Oncol. 2018 May;16(5):322-325.
9
Enasidenib for the treatment of acute myeloid leukemia.
Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760. doi: 10.1080/17512433.2018.1477585. Epub 2018 Jul 24.
10
In brief: Two new drugs for AML.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):e56.
引用本文的文献
1
Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
Leuk Res. 2022 Dec;123:106970. doi: 10.1016/j.leukres.2022.106970. Epub 2022 Oct 22.
Zotero 插件